ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016
Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Identification of hub genes and pathways in Uterine corpus endometrial carcinoma (UCEC): A comprehensiveBiochemistry and biophysics reports · 2024Article
- Article
- Association of insulin-like growth factor II mrna-binding protein 3 (IMP3) expression with prognostic and morphological factors in endometrial cancer.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024Article
- ImmuneScore of eight-gene signature predicts prognosis and survival in patients with endometrial cancer.Frontiers in oncology · 2023Article
- Article
- Construction of a nine DNA repair-related gene prognostic classifier to predict prognosis in patients with endometrial carcinoma.BMC cancer · 2021Article
- Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature.Frontiers in cell and developmental biology · 2021Article
- Construction and Validation of a Ferroptosis-Related Prognostic Model for Endometrial Cancer.Frontiers in genetics · 2021Article
- Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2020Review
- Novel miRNA markers for the diagnosis and prognosis of endometrial cancer.Journal of cellular and molecular medicine · 2020Article
- Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.British journal of cancer · 2020Article
- Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data.Scientific reports · 2019Article
- Ultrasound microbubble-mediated CRISPR/Cas9 knockout of C-erbB-2 in HEC-1A cells.The Journal of international medical research · 2019Article
- Establishment of a nine-gene prognostic model for predicting overall survival of patients with endometrial carcinoma.Cancer medicine · 2018Article
- Predicting high-risk endometrioid carcinomas using proteins.Oncotarget · 2018Article
- Exploration of DNA methylation markers for diagnosis and prognosis of patients with endometrial cancer.Epigenetics · 2018Article
- Article
- Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs.Nature communications · 2017Article
- Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer.Seminars in oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
purposeEndometrioid endometrial carcinoma (EEC) is the major histologic type of endometrial cancer, the most prevalent gynecologic malignancy in the United States. EEC recurrence or metastasis is associated with a poor prognosis. Early-stage EEC is generally curable, but a subset has high risk of recurrence or metastasis. Prognosis estimation for early-stage EEC mainly relies on clinicopathologic characteristics, but is unreliable. We aimed to identify patients with high-risk early-stage EEC who are most likely to benefit from more extensive surgery and adjuvant therapy by building a prognostic model that integrates clinical variables and protein markers. EXPERIMENTAL
designWe used two large, independent early-stage EEC datasets as training (n = 183) and validation cohorts (n = 333), and generated the levels of 186 proteins and phosphoproteins using reverse-phase protein arrays. By applying an initial filtering and the elastic net to the training samples, we developed a prognostic model for overall survival containing two clinical variables and 18 protein markers and optimized the risk group classification.
resultsThe Kaplan-Meier survival analyses in the validation cohort confirmed an improved discriminating power of our prognostic model for patients with early-stage EEC over key clinical variables (log-rank test, P = 0.565 for disease stage, 0.567 for tumor grade, and 1.3 × 10(-4) for the integrative model). Compared with clinical variables (stage, grade, and patient age), only the risk groups defined by the integrative model were consistently significant in both univariate and multivariate analyses across both cohorts.
conclusionsOur prognostic model is potentially of high clinical value for stratifying patients with early-stage EEC and improving their treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.